Non-small cell lung cancer in 2026: A narrative review of clinical advances and systemic challenges
Disease and Therapeutics · 2026 · 2 · 100010
DOI: 10.1016/j.dist.2026.100010 ↗Kurz gefasst
Fachartikel in der Zeitschrift Disease and Therapeutics, 2026. Verfasst von Connor Frey. Die Arbeit nennt 92 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Non-small cell lung cancer management has undergone a fundamental transformation, driven by the simultaneous maturation of targeted therapy, antibody-drug conjugates, and immune checkpoint inhibition across all disease stages. Comprehensive molecular profiling via next-generation sequencing now guides treatment selection for the majority of patients with adenocarcinoma, with actionable alterations identified in over 60% of cases. Key advances include the perioperative extension of osimertinib and alectinib into resected EGFR-mutated and ALK-positive disease, respectively, and the establishment of osimertinib consolidation following chemoradiotherapy in unresectable stage III EGFR-mutated NSCLC. Zongertinib received accelerated FDA approval for HER2-mutant disease, offering a selective oral option with meaningful CNS activity. Datopotamab deruxtecan and telisotuzumab vedotin further established antibody-drug conjugates as a validated treatment pillar. Perioperative immunotherapy with pembrolizumab, durvalumab, and nivolumab-based regimens now carries NCCN category 1 recommendations for resectable, driver-negative disease. Despite these advances, acquired resistance, sequencing complexity, and inequitable access to molecular diagnostics and novel therapeutics remain consequential challenges. Realising the full population-level benefit of this therapeutic progress requires concurrent investment in diagnostic infrastructure, health equity frameworks, and streamlined reimbursement pathways.
Zitieren
APA
Frey, C. (2026). Non-small cell lung cancer in 2026: A narrative review of clinical advances and systemic challenges. Disease and Therapeutics, 2, 100010. https://doi.org/10.1016/j.dist.2026.100010
Vancouver
Frey C. Non-small cell lung cancer in 2026: A narrative review of clinical advances and systemic challenges. Disease and Therapeutics. 2026;2:100010. doi:10.1016/j.dist.2026.100010
BibTeX
@article{Frey2026,
author = {Frey, Connor},
title = {Non-small cell lung cancer in 2026: A narrative review of clinical advances and systemic challenges},
journal = {Disease and Therapeutics},
year = {2026},
volume = {2},
pages = {100010},
doi = {10.1016/j.dist.2026.100010}
}
EUVIMED